| Date | Title | Description | Source |
| 23.04.2024 | New report presents good figures from the Swiss biotech sect... |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is qu... | startuptic... |
| 20.03.2024 | FDA approvals and encouraging results for innovative therapi... |
Idorsia announced today that the US Food and Drug Administration (FDA) has approved TRYVIO (aprocit... | startuptic... |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapie... | startuptic... |
| 28.02.2024 | Idorsia and Viatris enter into a significant global research... | Ad hoc announcement pursuant to Art. 53 LR
Viatris and Idorsia will collaborate on the global develo... | einpresswi... |
| 20.07.2023 | Idorsia sells its Asia Pacific operations to Sosei Heptares ... | | startuptic... |
| 20.06.2023 | Fresh money for Santhera and Idorsia | | startuptic... |
| 06.04.2023 | Idorsia issues invitation to the 2023 Annual General Meeting... | Allschwil, Switzerland – April 6, 2023
Idorsia Ltd IDIA today issued the invitation to the upcoming ... | einpresswi... |
| 31.01.2023 | Idorsia submits European marketing authorisation application... | The application includes data from the Phase 3 registration study of patients with resistant hyperte... | einpresswi... |
| 20.12.2022 | Idorsia submits a New Drug Application to the US FDA for apr... | The application includes data from the Phase 3 registration study of patients with resistant hyperte... | einpresswi... |
| 20.12.2022 | Idorsia submits a New Drug Application to the US FDA for apr... | The application includes data from the Phase 3 registration study of patients with resistant hyperte... | einpresswi... |
| 12.12.2022 | Long-term safety and tolerability results with daridorexant ... | Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (... | einpresswi... |
| 12.12.2022 | Long-term safety and tolerability results with daridorexant ... | Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (... | einpresswi... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for dar... | NANJING, China, Nov. 16, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simce... | en.prnasia... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for dar... | NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simce... | einpresswi... |
| 15.11.2022 | Idorsia’s insomnia drug available in first European countrie... | | startuptic... |
| 13.11.2022 | Idorsia congratulates its Chief Scientific Officer Martine C... | Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and... | einpresswi... |
| 25.10.2022 | Idorsia announces financial results for the first nine month... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 25, 2022
Idorsia Ltd (SI... | globenewsw... |
| 20.10.2022 | Invitation to Idorsia's nine-month financial results 2022 we... | Idorsia will publish its financial results for the first nine months of 2022 on October 25, 2022, at... | globenewsw... |
| 03.10.2022 | Idorsia Japan announces positive results with daridorexant i... | Ad hoc announcement pursuant to Art. 53 LR
Daridorexant demonstrated significant improvement in the ... | globenewsw... |
| 12.09.2022 | Six New Member Companies Join the International Consortium f... | IQ continues to grow as an organization and advance key industry initiatives while delivering innova... | prweb.com/... |
| 26.07.2022 | Idorsia announces financial results for the first half 2022 ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 26, 2022
Idorsia Ltd (SIX: ... | globenewsw... |
| 19.07.2022 | Invitation to Idorsia's half year financial results 2022 web... | Idorsia will publish its half year financial results 2022 on Tuesday July 26, 2022, at 07:00 CEST.
A... | globenewsw... |
| 23.05.2022 | Idorsia claims PhIII win for hypertension drug at cent... | Months after earning its first approval, Idorsia is back with a Phase III win for a different,... | endpts.com... |
| 03.05.2022 | Europe’s first dual orexin receptor antagonist – QUVIVIQ (da... | QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms p... | globenewsw... |
| 02.05.2022 | Idorsia’s new treatment QUVIVIQ (daridorexant) is now availa... | In the US, QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of ad... | globenewsw... |
| 26.04.2022 | Idorsia announces financial results for the first quarter 20... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – April 26, 2022
Idorsia Ltd (SIX:... | globenewsw... |
| 14.04.2022 | Idorsia holds its Annual General Meeting of Shareholders | Ad hoc announcement pursuant to Art. 53 LR
All Board proposals approved by the Shareholders
Allschwi... | globenewsw... |
| 07.04.2022 | Eldico Scientific opens world’s first experience centre for ... | | startuptic... |
| 04.04.2022 | The Journal of Neurosurgery reports impact of clazosentan on... | Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the com... | globenewsw... |
| 10.03.2022 | New data for daridorexant in patients with insomnia disorder... | Allschwil, Switzerland – March 10, 2022
Idorsia Ltd (SIX: IDIA) today announced that new data for da... | globenewsw... |
| 03.03.2022 | Idorsia issues Notice of the 2022 Annual General Meeting of ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – March 3, 2022
Idorsia Ltd (SIX: ... | globenewsw... |
| 08.02.2022 | Idorsia announces financial results for 2021 – 2022 to be a ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – February 8, 2022
Idorsia Ltd (SI... | marketscre... |
| 08.02.2022 | Idorsia announces financial results for 2021 – 2022 to be a ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – February 8, 2022
Idorsia Ltd (SI... | globenewsw... |
| 08.02.2022 | Idorsia : Download (2.5MB) | Governance Report
20
21ANNUAL REPORT
The purpose of Idorsia is to discover, develop and commercializ... | marketscre... |
| 01.02.2022 | Invitation to Idorsia's full year financial results 2021 web... | Idorsia will publish its full year financial results 2021 on Tuesday February 8, 2022, at 07:00 CET.... | globenewsw... |
| 26.01.2022 | Idorsia expands its commercialization partnership with Syneo... | Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ... | globenewsw... |
| 24.01.2022 | Idorsia appoints Guy Braunstein to Chief Medical Officer and... | Ad hoc announcement pursuant to Art. 53 LR
Idorsia appoints Guy Braunstein to Chief Medical Officer ... | globenewsw... |
| 20.01.2022 | The Lancet Neurology reports impact of daridorexant on both ... | The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioni... | globenewsw... |
| 20.01.2022 | Idorsia receives Japanese PMDA approval of PIVLAZ (clazosent... | Ad hoc announcement pursuant to Art. 53 LR
Idorsia receives Japanese PMDA approval of PIVLAZ (clazos... | globenewsw... |
| 20.01.2022 | Idorsia : The Lancet Neurology reports impact of daridorexan... | Media Release
January 20, 2022
The Lancet Neurology reports impact of daridorexant on both nighttime... | marketscre... |
| 12.01.2022 | Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize... | Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring... | globenewsw... |
| 10.01.2022 | Idorsia presents at the 40th J.P. Morgan Healthcare Conferen... | Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – ... | globenewsw... |
| 10.01.2022 | Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 2... | Ad hoc announcement pursuant to Art. 53 LR
Idorsia receives US FDA approval of QUVIVIQ (daridorexant... | globenewsw... |
| 10.01.2022 | FDA approves Idorsia’s insomnia drug | | startuptic... |
| 13.12.2021 | Idorsia to further characterize lucerastat for the treatment... | Ad hoc announcement pursuant to Art. 53 LR
Idorsia to further characterize lucerastat for the treatm... | globenewsw... |
| 01.11.2021 | Idorsia to advance cenerimod into Phase 3 development for tr... | Ad hoc announcement pursuant to Art. 53 LR
Cenerimod 4 mg showed clinically meaningful improvement i... | globenewsw... |
| 27.10.2021 | Johnson & Johnson partially converts its convertible loa... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 27, 2021
Idorsia Ltd (SI... | globenewsw... |
| 26.10.2021 | Press Release : Idorsia announces financial -3- | ACT-777991 - Immunology Phase 1 ------------- ---------------- -------------------------------------... | marketscre... |
| 26.10.2021 | Idorsia : announces financial results for the third quarter ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 26, 2021
Idorsia Ltd (SI... | marketscre... |
| 26.10.2021 | Idorsia announces financial results for the third quarter 20... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 26, 2021
Idorsia Ltd (SI... | globenewsw... |
| 26.10.2021 | Press Release : Idorsia announces financial -2- | On July 28, 2021, Idorsia placed CHF 600 million senior unsecured convertible bonds (the "Bonds... | marketscre... |
| 26.10.2021 | Idorsia : Financial Report Nine-Month 2021 | Financial
Report
20
21NINE-MONTH
The purpose of Idorsia is to discover, develop and commercialize in... | marketscre... |
| 11.10.2021 | Idorsia : announces the results of MODIFY, a Phase 3 study o... | Media Release
October 11, 2021
Ad hoc announcement pursuant to Art. 53 LR
Idorsia announces the resu... | marketscre... |
| 11.10.2021 | Idorsia announces the results of MODIFY, a Phase 3 study of ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 11, 2021
Idorsia Ltd (SI... | globenewsw... |
| 28.07.2021 | Press Release : Idorsia launches the offering of convertible... | Ad hoc announcement pursuant to Art. 53 LR
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE... | marketscre... |
| 28.07.2021 | Idorsia : successfully completes the offering of convertible... | Media Release
July 28, 2021
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES,... | marketscre... |
| 28.07.2021 | Idorsia : launches the offering of convertible bonds to fund... | Media Release
July 28, 2021
Ad hoc announcement pursuant to Art. 53 LR
NOT FOR RELEASE, PUBLICATION,... | marketscre... |
| 27.07.2021 | Idorsia : Media Release (English) | Media Release
July 27, 2021
Ad hoc announcement pursuant to Art. 53 LR
Idorsia announces financial r... | marketscre... |
| 27.07.2021 | Idorsia announces financial results for the first half 2021 ... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 27, 2021
Idorsia Ltd (SIX: ... | marketscre... |
| 27.07.2021 | Press Release : Idorsia announces financial -2- | At the end of the first half of 2021, Idorsia's liquidity (including cash, cash equivalents, short- ... | marketscre... |
| 28.06.2021 | Idorsia initiates the Phase 3 registration study with selato... | Ad hoc announcement pursuant to Art. 53 LR
Idorsia to host an investor webcast to discuss the Phase ... | marketscre... |
| 22.04.2021 | IDORSIA LTD
Press Release : Idorsia announces financial -2- | --------------------------- ------------ ------------ ------------ Long-term deposits 196 192 180 --... | marketscre... |
| 01.04.2021 | IDORSIA LTD
Press Release: Idorsia issues Notice of the 202... | Allschwil, Switzerland -- April 1, 2021 Idorsia Ltd (SIX: IDIA) today issued the formal Notice to th... | marketscre... |
| 01.04.2021 | IDORSIA LTD
Idorsia : issues Notice of the 2021 Annual Gene... | Allschwil, Switzerland – April 1, 2021
Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the... | marketscre... |
| 10.03.2021 | FDA accepts the new drug application for review of Idorsia’s... | • The application includes robust data from the Phase 3 registration program, which demonstrated eff... | globenewsw... |
| 01.03.2021 | Idorsia submits NDA for clazosentan to Japanese PMDA | Allschwil, Switzerland – March 1, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a N... | globenewsw... |
| 04.02.2021 | Press Release : Idorsia announces financial -2- | binge-like eating behavior in animal models. Our study will be the first to study orexin 1 receptor ... | marketscre... |
| 04.02.2021 | IDORSIA LTD
Press Release : Idorsia announces financial -2- | binge-like eating behavior in animal models. Our study will be the first to study orexin 1 receptor ... | marketscre... |
| 04.02.2021 | Idorsia : announces financial results for 2020 – a successfu... | Allschwil, Switzerland – February 4, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial resu... | marketscre... |
| 04.02.2021 | IDORSIA LTD
Idorsia : announces financial results for 2020 ... | Allschwil, Switzerland – February 4, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial resu... | marketscre... |
| 22.10.2020 | Idorsia completes capital increase of CHF 535.5 million | Idorsia Ltd announced that a total of 23,800,000 new shares were sold in connection with the at-mark... | startuptic... |
| 22.10.2020 | Idorsia completes capital increase of CHF 535.5 million | | startuptic... |
| 21.10.2020 | IDORSIA LTD
Idorsia : raises $600 million to support insomn... | Idorsia plans to file for approval for daridorexant in the United States later this year and is alre... | marketscre... |
| 23.07.2020 | IDORSIA LTD
Idorsia announces financial results for the fir... | Allschwil, Switzerland – July 23, 2020
Idorsia Ltd (SIX: IDIA) today announced its financial results... | marketscre... |
| 06.07.2020 | IDORSIA LTD
Idorsia announces positive results in the secon... | Results confirm and reinforce the efficacy and safety profile from the first pivotal study
Company t... | marketscre... |
| 20.05.2020 | Idorsia raises CHF 330 million in new share offering | Idorsia placed 11 million new registered shares of CHF 0.05 par value each at CHF 30 per new share (... | startuptic... |
| 20.05.2020 | Idorsia raises CHF 330 million in new share offering | | startuptic... |
| 20.04.2020 | Idorsia announces positive Phase 3 results for its lead prod... | Insomnia is, worldwide, the most commonly reported sleep disorder and its impact is often underestim... | startuptic... |
| 20.04.2020 | Pivotal data suggest clean safety profile, potency co... | Swiss biotech Idorsia, spun out of Actelion after J&J wrapped up its $30 billion takeover in... | endpts.com... |
| 20.04.2020 | Idorsia announces positive Phase 3 results for its lead prod... | | startuptic... |
| 18.04.2019 | Genfit wins BTD status at FDA for its lead drug for liver... | Pascal Birman
→ Genfit $GNFT is getting a helping hand from the FDA with its lead drug elafib... | endpts.com... |
| 21.12.2017 | Idorsia geht Forschungskooperation mit Roche ein | | startuptic... |
| 04.12.2017 | Idorsia collaborates with Janssen Biotech on aprocitentan | | startuptic... |
| 28.07.2017 | Idorsia touts new sleep drug data ahead of PhIII; Tetraph... | → Actelion spinout Idorsia says it scored positive data from two Phase II studies of a new sl... | endpts.com... |
